Long-term outcomes following Foscan®-PDT of basal cell carcinomas
Standard
Long-term outcomes following Foscan®-PDT of basal cell carcinomas. / Betz, Christian S; Rauschning, Winrich; Stranadko, Evgueni Ph; Riabov, Mikhail V; Volgin, Valery N; Albrecht, Volker; Nifantiev, Nikolay E; Hopper, Colin.
in: LASER SURG MED, Jahrgang 44, Nr. 7, 09.2012, S. 533-40.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Long-term outcomes following Foscan®-PDT of basal cell carcinomas
AU - Betz, Christian S
AU - Rauschning, Winrich
AU - Stranadko, Evgueni Ph
AU - Riabov, Mikhail V
AU - Volgin, Valery N
AU - Albrecht, Volker
AU - Nifantiev, Nikolay E
AU - Hopper, Colin
N1 - Copyright © 2012 Wiley Periodicals, Inc.
PY - 2012/9
Y1 - 2012/9
N2 - BACKGROUND AND OBJECTIVE: In a previous publication we showed that mTHPC-PDT (Foscan®-PDT) is an effective treatment of basal cell carcinomas (BCCs) in "difficult to treat" locations and presented optimized treatment parameters to reduce costs and side effects. Now we present long-term results of the same study population.STUDY DESIGN/MATERIALS AND METHODS: Following PDT of a total of 460 BCCs in 117 subjects, the patients/lesions were followed-up for a mean duration of 42 (range: 2-72) months. Two patients dropped out of follow-up; 13 patients died of unrelated causes. Recurrences were treated either by repeated PDT or other established methods.RESULTS: The sustained clearance rate was 93.7% and the overall treatment success rate was 90.7%. Kaplan-Meier analysis revealed an estimated recurrence free fraction of patients at 5 years of 95.1%, 92.4%, 85.1%, and 74.0% for the four different photosensitizer dose groups (0.06-0.15, 0.05, 0.04, and 0.03 mg/kg). High-risk lesions (recurrences, thickness >3 mm) recurred more often than low-risk ones, and recurrences mostly (>50%) occurred during the first year of follow-up.CONCLUSION: Long-term outcomes of high-dose (0.06-0.15 mg/kg) and reduced-dose (0.05 mg/kg) Foscan®-PDT in "difficult to treat" BCCs compare favorably with other methods, even in high-risk lesions (recurrent and/or thick lesions). A recommended combination of treatment parameters for low-dose therapy seems to be: 0.05 mg/kg Foscan®, 24 hours drug-light interval (DLI), fluence ≥40 J/cm(2) . Prospective randomized studies are needed to look into low-dose mTHPC-PDT of BCCs in more detail and to directly compare it with other treatments.
AB - BACKGROUND AND OBJECTIVE: In a previous publication we showed that mTHPC-PDT (Foscan®-PDT) is an effective treatment of basal cell carcinomas (BCCs) in "difficult to treat" locations and presented optimized treatment parameters to reduce costs and side effects. Now we present long-term results of the same study population.STUDY DESIGN/MATERIALS AND METHODS: Following PDT of a total of 460 BCCs in 117 subjects, the patients/lesions were followed-up for a mean duration of 42 (range: 2-72) months. Two patients dropped out of follow-up; 13 patients died of unrelated causes. Recurrences were treated either by repeated PDT or other established methods.RESULTS: The sustained clearance rate was 93.7% and the overall treatment success rate was 90.7%. Kaplan-Meier analysis revealed an estimated recurrence free fraction of patients at 5 years of 95.1%, 92.4%, 85.1%, and 74.0% for the four different photosensitizer dose groups (0.06-0.15, 0.05, 0.04, and 0.03 mg/kg). High-risk lesions (recurrences, thickness >3 mm) recurred more often than low-risk ones, and recurrences mostly (>50%) occurred during the first year of follow-up.CONCLUSION: Long-term outcomes of high-dose (0.06-0.15 mg/kg) and reduced-dose (0.05 mg/kg) Foscan®-PDT in "difficult to treat" BCCs compare favorably with other methods, even in high-risk lesions (recurrent and/or thick lesions). A recommended combination of treatment parameters for low-dose therapy seems to be: 0.05 mg/kg Foscan®, 24 hours drug-light interval (DLI), fluence ≥40 J/cm(2) . Prospective randomized studies are needed to look into low-dose mTHPC-PDT of BCCs in more detail and to directly compare it with other treatments.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Carcinoma, Basal Cell
KW - Drug Administration Schedule
KW - Female
KW - Follow-Up Studies
KW - Humans
KW - Kaplan-Meier Estimate
KW - Lasers, Semiconductor
KW - Male
KW - Mesoporphyrins
KW - Middle Aged
KW - Neoplasm Recurrence, Local
KW - Photochemotherapy
KW - Photosensitizing Agents
KW - Skin Neoplasms
KW - Treatment Outcome
KW - Evaluation Studies
KW - Journal Article
U2 - 10.1002/lsm.22056
DO - 10.1002/lsm.22056
M3 - SCORING: Journal article
C2 - 22851213
VL - 44
SP - 533
EP - 540
JO - LASER SURG MED
JF - LASER SURG MED
SN - 0196-8092
IS - 7
ER -